Investigating Ozempic The case for PERSONALISED DOSES of Ozempic and Wegovy for successful weight loss
Mar 5, 2025
The podcast dives into the intricacies of how personalized dosing of Ozempic and Wegovy could transform weight loss outcomes. It highlights the factors influencing individual responses to these medications, posing questions about why two vastly different individuals might receive the same dosage. Recent FDA updates on drug shortages are also discussed, revealing their impact on patients seeking tailored solutions. It's a thought-provoking look at how we can rethink weight loss treatments.
AI Snips
Chapters
Transcript
Episode notes
Uniform Dosage for Different Weights
- A 250 kilo man and a 100 kilo woman both receive the same dosing schedule of semaglutide from a doctor.
- This prescribing practice does not take into account their very different body sizes and needs.
Body Weight Impacts Drug Exposure
- Body weight significantly affects semaglutide exposure; heavier people have less drug exposure in their bodies.
- Despite this, dosing is not adjusted by weight, causing major differences in drug impact between individuals.
Sex Differences Affect Dosage Response
- Women generally have higher semaglutide exposure and more gastric side effects than men at the same dose.
- Differences in body composition, metabolism, and gastric emptying contribute to this sex-based variability.